{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:49:32Z","timestamp":1793904572492,"version":"4.8.0"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Pediatric cataracts are a main cause of irreversible vision loss and a significant public health challenge. This study aimed to identify pharmacovigilance signals by analyzing large-scale data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Using real-world data from FAERS (Q1 2004 to Q3 2025), we investigated associations between medications and pediatric cataracts. Following data standardization, signal detection was performed using multiple disproportionality analyses, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). The time to onset was also evaluated. Results: Among 690,374 reports for individuals aged 0\u201317 years, 671 reports involving 232 drugs were reported with cataracts. Disproportionality analysis identified 24 drugs with significant signals, predominantly glucocorticoids (11\/24), followed by immunosuppressants, monoclonal antibodies, cystic fibrosis transmembrane conductance regulator (CFTR) modulators, antineoplastic agents, an antiepileptic drug, and a colony-stimulating factor. Difluprednate showed the highest pharmacovigilance signal (ROR: 963.67; 95% CI: 316.27\u20132936.31; n = 4). Notably, CFTR modulators exhibited striking signals: ivacaftor (ROR: 30.75; 95% CI: 18.06\u201352.37; n = 14), elexacaftor-ivacaftor-tezacaftor (ROR: 15.58; 95% CI: 9.86\u201324.63; n = 19), and ivacaftor-lumacaftor (ROR: 13.2; 95% CI: 7.9\u201322.07; n = 15). Conclusions: This study provides a comprehensive large-scale pharmacovigilance profile of drug-induced pediatric cataracts, identifying agents with high-risk pharmacovigilance signals and underscoring the need for proactive ocular monitoring. These findings can inform clinical decision making and prevention strategies and guide future mechanistic research.<\/jats:p>","DOI":"10.3390\/children13020243","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:42:42Z","timestamp":1770640962000},"page":"243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Jiantong","family":"Du","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.earlhumdev.2007.09.014","article-title":"The development of vision","volume":"83","author":"Mercuri","year":"2007","journal-title":"Early Hum. Dev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(17)30544-5","article-title":"Cataracts","volume":"390","author":"Liu","year":"2017","journal-title":"Lancet"},{"key":"ref_3","first-page":"92","article-title":"Lens epithelial cell proliferation in response to ionizing radiation","volume":"197","author":"Barnard","year":"2022","journal-title":"Radiat. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/archdischild-2016-310532","article-title":"Epidemiology of blindness in children","volume":"102","author":"Solebo","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4103\/ijo.IJO_1023_17","article-title":"Pediatric cataract","volume":"65","author":"Khokhar","year":"2017","journal-title":"Indian J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2419366","DOI":"10.1001\/jamanetworkopen.2024.19366","article-title":"Cataract Development Among Pediatric Patients with Uveitis","volume":"7","author":"Hsu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rogerson, T., Ath, S.S., Meng, N., and Casson, R. (2024). A 12-year follow up survey of childhood blindness at schools for the blind in Cambodia. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03285-0"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ji, Z., Wang, X., and Wang, J. (2025). Analysis of off-label drug use and its influencing factors in pediatric patients undergoing otolaryngology, head, and neck surgery. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1553221"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014Drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41433-020-1115-6","article-title":"Cataract management in children: A review of the literature and current practice across five large UK centres","volume":"34","author":"Self","year":"2020","journal-title":"Eye"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41433-023-02749-9","article-title":"Childhood traumatic cataract in Nigeria; a multicentre study: 2017\u20132021","volume":"38","author":"Muhammad","year":"2024","journal-title":"Eye"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100229","DOI":"10.1016\/j.apjo.2025.100229","article-title":"Update on pediatric cataract surgery","volume":"14","author":"Lloyd","year":"2025","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, X., Wang, S.W., Zhang, Z.J., Luo, Z.Y., Tang, J.F., and Tao, T. (2025). Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1498191"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/j.jcrs.0000000000001738","article-title":"Primary Suspect Drugs of Cataracts in Pediatric Patients: An FDA Adverse Events Reporting Database Analysis","volume":"51","author":"Ali","year":"2025","journal-title":"J. Cataract. Refract. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E2329074","DOI":"10.1001\/jamanetworkopen.2023.29074","article-title":"Adverse drug events by sex after adjusting for baseline rates of drug use","volume":"6","author":"Rushovich","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E199249","DOI":"10.1001\/jamanetworkopen.2019.9249","article-title":"Adverse events associated with the use of sipuleucel-T reported to the US Food and Drug Administration\u2019s Adverse Event Reporting System, 2010\u20132017","volume":"2","author":"Dores","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103385","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: A pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: Implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sheidaei, A., Foroushani, A.R., Gohari, K., and Zeraati, H. (2022). A novel dynamic Bayesian network approach for data mining and survival data analysis. BMC Med. Inform. Decis. Mak., 22.","DOI":"10.1186\/s12911-022-02000-7"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0039-6257(96)82011-X","article-title":"Infantile cataracts","volume":"40","author":"Lambert","year":"1996","journal-title":"Surv. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Green, M.B., and Duker, J.S. (2023). Adverse Ocular Effects of Systemic Medications. Life, 13.","DOI":"10.3390\/life13030660"},{"key":"ref_26","unstructured":"Vertex Pharmaceuticals (2012). Kalydeco (Ivacaftor) Prescribing Information, Vertex Pharmaceuticals Incorporated."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration (2026, January 04). April\u2013June 2023|Potential Signals of Serious Risks\/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/april-june-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event."},{"key":"ref_28","first-page":"305","article-title":"Toxicity to intravitreal melphalan in a patient with retinoblastoma","volume":"67","year":"2023","journal-title":"Rom. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to gold standard","volume":"96","author":"Munier","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/pbc.22277","article-title":"Ocular late effects in childhood cancer survivors: A report from the Childhood Cancer Survivor Study","volume":"54","author":"Whelan","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1007\/s00277-024-05678-z","article-title":"Advances in the ocular complications after hematopoietic stem cell transplantation","volume":"103","author":"Lv","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"26921","DOI":"10.1038\/s41598-025-10924-z","article-title":"Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System","volume":"15","author":"Hong","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1167\/iovs.13-12660","article-title":"Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: A phase III, multicenter, randomized study","volume":"55","author":"Sheppard","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus Methotrexate for JIA-associated Uveitis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/DDDT.S160431","article-title":"Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: A meta-analysis and systematic review","volume":"12","author":"Ming","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kulbay, M., Wu, K.Y., Nirwal, G.K., B\u00e9langer, P., and Tran, S.D. (2024). Oxidative Stress and Cataract Formation: Evaluating the Efficacy of Antioxidant Therapies. Biomolecules, 14.","DOI":"10.3390\/biom14091055"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"P184","DOI":"10.1016\/j.ophtha.2017.09.032","article-title":"Pediatric Eye Evaluations Preferred Practice Pattern: I. Vision Screening in the Primary Care and Community Setting; II. Comprehensive Ophthalmic Examination","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/2\/243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:22:27Z","timestamp":1770643347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/2\/243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["children13020243"],"URL":"https:\/\/doi.org\/10.3390\/children13020243","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}